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1
1 Emerging roles of melanocortin receptor accessory proteins (MRAP and 
2 MRAP2) in physiology and pathophysiology.
3
4 Abstract:
5 Melanocortin-2 receptor accessory protein (MRAP) has an unusual dual topology and 
6 influences the expression, localisation, signalling and internalisation of the 
7 melanocortin receptor 2 (MC2); the adrenocorticotropic hormone (ACTH) receptor. 
8 Mutations in MRAP are associated with familial glucocorticoid deficiency type-2 and 
9 evidence is emerging of the importance of MRAP in adrenal development and ACTH 
10 signalling. Human MRAP has two functional splice variants: MRAP-α and MRAP-β, 
11 unlike MRAP-β, MRAP-α has little expression in brain but is highly expressed in ovary. 
12 MRAP2, identified through whole human genome sequence analysis, has 
13 approximately 40% sequence homology to MRAP. MRAP2 facilitates MC2 localisation 
14 to the cell surface but not ACTH signalling. MRAP and MRAP2 have been found to 
15 regulate the surface expression and signalling of all melanocortin receptors (MC1-5). 
16 Additionally, MRAP2 moderates the signalling of the G-protein coupled receptors 
17 (GCPRs): orexin, prokineticin and GHSR1a; the ghrelin receptor.
18 Whilst MRAP appears to be mainly involved in glucocorticoid synthesis, an important 
19 role is emerging for MRAP2 in regulating appetite and energy homeostasis. 
20 Transgenic models indicate the importance of MRAP in adrenal gland formation. Like 
21 MC3R and MC4R knockout mice, MRAP2 knockout mice have an obese phenotype. 
22 In vitro studies indicate that MRAP2 enhances the MC3 and MC4 response to the 
23 agonist αMSH, which, like ACTH, is produced through precursor polypeptide 
24 proopiomelanocortin (POMC) cleavage. Analysis of cohorts of individuals with obesity 
25 have revealed several MRAP2 genetic variants with loss of function mutations which 
26 are causative of monogenic hyperphagic obesity with hyperglycaemia and 
27 hypertension. MRAP2 may also be associated with female infertility. This review 
28 summarises current knowledge of MRAP and MRAP2, their influence on GPCR 
29 signalling, and focusses on pathophysiology, particularly familial glucocorticoid 
30 deficiency type-2 and obesity.
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40 Genetic variants of melanocortin-2 receptor accessory protein (MRAP) are associated 
41 with severe glucocorticoid deficiency (Metherell, et al., 2005). Adrenocorticotropic 
42 hormone (ACTH) is the endogenous agonist for the melanocortin receptor 2 (MC2), a 
43 class A G-protein coupled receptor. MRAP is a small transmembrane protein which 
44 promotes the assembly of melanocortin receptor 2 in the endoplasmic reticulum and 
2
45 stabilises MC2 in the plasma membrane. MRAP influences the binding of ACTH to 
46 MC2 and following agonist stimulation, MC2 via Gs protein, activates adenylate cyclase 
47 generating cyclic adenosine monophosphate (cAMP). 
48
49 Effective ACTH signalling is vital to produce steroids including glucocorticoid, hence 
50 genetic variants of MRAP are linked to familial glucocorticoid deficiency. MRAP 
51 expression is high in the brain and the adrenal gland and MRAP has been 
52 demonstrated to affect the differentiation of progenitor cells within the adrenal gland 
53 (Novoselova, et al., 2018).
54 MRAP2 shares approximately 40% sequence homology with MRAP but unlike MRAP, 
55 which facilitates MC2 localisation and signalling; MRAP2 has less receptor fidelity, 
56 influencing the signalling of melanocortin receptors (MC1-5), as well as orexin receptor, 
57 ghrelin receptor and growth hormone secretagogue receptor 1a (GHSR-1a) (Srisai, et 
58 al., 2017). MC3 and MC4 both have important roles in appetite control with deficiencies 
59 linked to obesity (Chen, et al., 2000). The MC4 agonist setmelanotide is currently in 
60 phase 3 clinical trials for rare genetic disorders of obesity caused by mutations in 
61 proopiomelanocortin (POMC) (Kühnen, et al., 2016) and leptin receptor (LEPR) 
62 (Clément, et al., 2018). Evidence from in vitro analyses, MRAP2 transgenic animals 
63 and MRAP2 variants in populations with metabolic syndrome (Baron, et al., 2019), 
64 indicate that MRAP2 has an important role regulating appetite control, with MRAP2 
65 genetic variants causing obesity.
66
67 This article will review the structures of melanocortin receptor accessory proteins, 
68 physiological roles, and emerging evidence about the MRAP and MRAP2 genetic 




73 MRAP is a hydrophobic single pass transmembrane protein which is encoded for by 
74 a single gene located on chromosome 21q22.11 (Xu, et al., 2002) composed of 6 
75 exons. There are two functional MRAP splice variants: MRAP-α derived from exon 1-
76 5 which is 172 amino acids (19 kDa) and MRAP-β derived from exon 1-4, 6, which is 
77 102 amino acids (14.1 kDa). These splice variants have conserved N-terminal 
78 homology but differ at the C-terminus (Xu, et al., 2002; Metherell, et al., 2005) 
79 When first described, it was predicted that the MRAP dimer would orientate with 
80 intracellular N-terminus and extracellular C-terminus (Metherell, et al., 2005). 
81 However, through epitope immunoprecipitation and live cell imaging studies the 
82 quaternary structure of the MRAP was found to form a stable anti-parallel homodimer 
83 with N-termini orientating both intracellularly and extracellularly, which is still thought 
84 to be unique in eukaryotes (Sebag and Hinkle, 2007).
85  MRAP is partially glycosylated and this is dependent upon the Asn-X-Ser/Thr motif 
86 facing the luminal surface of the endoplasmic reticulum (Sebag and Hinkle, 2007), 
3
87 however, the creation of functional MRAP glycosylation mutants in this study 
88 determined that glycosylation was not necessary for dual topology.
89
90 A further series of mutational studies identified the N-terminal 31-37 sequence 
91 (LKANKHS) adjacent to the transmembrane region to be essential for this dual 
92 topology (Sebag, and Hinkle, 2009). Using bimolecular fluorescence 
93 complementation, Sebag and Hinkle demonstrated that this dual topology occurs in 
94 the endoplasmic reticulum; once formed this stable orientation is retained when the 
95 protein is expressed on the plasma membrane (Maben, et al., 2016).
96
97 The N-terminus and the transmembrane domains of MRAP are conserved between 
98 species however, the carboxyl region has greater variation (Agulleiro, et al., 2010). 
99 The 18-21 LDYI sequence is unique to the MRAP isoform and is required for the 
100 binding of ACTH to melanocortin receptor 2 (Sebag, and Hinkle, 2009) but MRAP C-
101 terminus truncation experiments suggested this domain has less impact on ACTH 
102 signalling (Sebag, and Hinkle, 2009). However, truncated MRAP (with the removal of 
103 the C-terminal domain), expressed in HEK293/FRT cells, revealed diminished MC2 
104 surface expression and cAMP production compared to full length MRAP; suggesting 
105 that the C-terminus does modulate MC2 cAMP generation in response to ACTH (Roy, 
106 et al., 2012). In addition serine and threonine residues in the C-terminus are necessary 
107 for MC2 internalisation and recycling (Roy, et al., 2011). The exact residues necessary 
108 for MRAPs to interact with GPCRs have not been fully characterised; however, co-
109 precipitation studies with MC2 suggest that the MRAP transmembrane domain is 
110 necessary (Webb, et al., 2009).
111
112 Discovery, Structure and Characteristics of MRAP2
113 As a paralog to MRAP, MRAP2 was identified in the human genome after sequence 
114 analysis. The MRAP2 gene is located at 6q14.3 and encodes for a 205 amino acid 
115 protein, the sequence alignment of MRAP2 indicates approximately 40% homology 
116 with MRAP. The greatest sequence conservation lies at the N-terminal and within the 
117 transmembrane domain, whilst the carboxyl terminal differs greatly between these two 
118 proteins (Chan, et al., 2009). 
119 MRAP2 is a transmembrane protein that traverses the membrane once and as with 
120 the MRAP, MRAP2 could be found both on the surface membrane and subcellularly 
121 on the luminal surface of the endoplasmic reticulum (Sebag, and Hinkle, 2010). 
122 MRAP2 shares the dual orientation of the carboxyl and amino terminal forming an 
123 antiparallel homodimer (Figure 1). Interestingly, MRAP2 has been shown to form a 
124 heterodimer with the MRAP (Figure 1); a yellow fluorescent protein in bimolecular 
125 complementation studies revealed an antiparallel orientation of the MRAP-MRAP2 





130 Figure 1: Dual topology of MRAP homodimer, MRAP2 homodimer and MRAP/MRAP2 
131 heterodimer; the green transmembrane domain represents the structure and the dual 
132 topology with the amino (NH2) / carboxyl (COOH) both being located extracellularly 
133 and amino (NH2) / carboxyl (COOH) termini also intracellularly. This dual topology 
134 allows for homodimer (MRAP/MRAP; MRAP2/MRAP2) or heterodimer 
135 (MRAP/MRAP2; MRAP2/MRAP) formation. The LKANKS31-37 (orange shading) 
136 immediately before the transmembrane region is required for dual topology, the 




141 MRAP gene regulation
142
143 MRAP gene expression is upregulated by lipopolysaccharide (Gibbison, et al., 2015), 
144 ACTH (Liu, et al., 2013) and in adipocytes by PPARγ (peroxisome proliferator-
145 activated receptor gamma) (Kim, et al., 2013). Diurnal Mrap expression has been 
146 observed in rats, with Mrap mRNA correlating with the expression of circadian 
147 regulating genes (per1, per2 and CLOCK) (Spiga, et al., 2020). Since the MRAP 
148 mRNA half-life is shorter than MC2R, Clark and Chan, (2019) have proposed a 
149 model where MRAP may facilitate the transport of MC2 to the plasma membrane 
150 without necessitating de novo MRAP/MC2R expression.
151
152 Gnomon automated computational analysis of the 21q22.11 region of the 
153 GRCh38.p13 (Souvorov, et al., 2010) has predicted the presence of a novel MRAP 
154 antisense RNA 1 (MRAP-AS1; XR_937664.1). Whether this non-coding RNA has a 




158 Figure 2: Predicted non-coding RNA, MRAP-AS1 (XR_937664.1, shown in red) on 
159 chromosome 21q22.11 in relation to MRAP (blue)
160
161
162 The evolution of MRAPs
163
164 Phylogenetic studies have revealed the existence of the MRAPs orthologues in 
165 different piscine species: zebrafish, tetrapod and some bony fish subspecies 
166 (Valsalan, et al., 2012). Interestingly, whilst MRAP2 was found in the sea lamprey and 
167 cartilaginous fish, MRAP was absent which lead to a theory that MRAP2 gene 
168 duplication may have given rise to MRAP (Västermark, and Schiöth, 2011). However, 
169 cDNA blast analysis from the elephant shark genome project located the MRAP 
170 sequence (Venkatesh, et al., 2014) discrediting an MRAP2 ancestral role. Considering 
171 all these findings, the origin of the MRAPs genes is thought to be as a result of R2 
172 genome duplication events according to the evolution theory (Ohno et al., 1968); a 
173 comprehensive review of melanocortin receptor evolution has been presented by 
174 Dores (Dores, et al., 2016).
175
176 The presence of both MRAPs has been described in most mammals and chicken 
177 (Valsalan et al., 2012), the dual topology feature of MRAP and MRAP2 was conserved 
178 through the appearance of the motifs LKANKH (MRAP) and LKAHKY (MRAP2) in the 
179 orthologs of mice, chicken and zebrafish. Additionally, sequence alignment studies of 
180 all linages revealed the MRAP sequence to be shorter than the MRAP2 sequence, 
181 with the transmembrane domain being well conserved amongst all species examined.
182
183 Distribution of the MRAPs 
184
185 In humans reverse transcription PCR (RT-PCR) indicated that both isoforms are 
186 present at high levels in the adrenals, testis and breasts; with low expression in in the 
187 digestive system, heart, fat and skin (Metherell, et al., 2005). In humans, MRAP-α and 
188 MRAP-β were found expressed in the adipose tissue, breast, testis and adrenal cortex 
189 (see table 1).
190 Examining the “Human Protein Atlas (HPA)- RNA-seq” data of 95 human samples 
191 reveals a wide distribution of MRAP, with the highest expression levels observed in 
192 the adipose tissue and the adrenal gland. This is followed by the skin and the male 
193 reproductive organs whilst brain, heart, ovary and the kidney had a lower expression 
194 (Fagerberg, et al., 2014). Table 1 lists human tissues expressing the MRAP-α and 
195 MRAP-β. Along with the adrenal gland expression, MRAP2 was expressed in different 
196 parts of the brain at high levels, as shown in the HPA-RNA-seq data (Fagerberg, et 
6
197 al., 2014). MRAP2 was also found to be highly expressed in the female and male 
198 reproductive systems and stomach whilst endocrine glands, liver and peripheral blood 
199 had the lowest MRAP2 expression (Fagerberg, et al., 2014). 
200
201 As discussed above, the MRAPs are present in other species, including chicken, fish 
202 and mice (Zhang et al., 2017; Agulleiro et al., 2010; Asai et al., 2013; Valsalen et al 
203 2012). While the MRAP was widely distributed in the tissues of those species, the 




207 Table 1: Expression of MRAP-α, MRAP-β and MRAP2 in human tissues. +++: high 








Tissue MRAP-α MRAP-β MRAP2 Reference
Adrenal gland +++ +++ +++ Metherell et al., 2005 
Chan et al., 2009
Testis +++ +++ + Metherell et al., 2005
Adipose + + + Xu et al., 2002
Metherell et al., 2005 
Fagerberg et al., 2014
Breast +++ +++ - Metherell et al., 2005
Ovary +++ + + Fagerberg et al., 2014
Endometrium + + + Fagerberg et al., 
2014Fagerberg et al., 
2014
Digestive tract + + + Fagerberg et al., 2014
Liver + - - Metherell et al., 2005
Heart + - - Metherell et al., 2005
Fagerberg et al., 2014




















Gardinar et al., 2002 
Chan et al., 2009 
Fagerberg et al., 2014
Chaly et al., 2016
Pituitary gland + - +++ Chaly et al., 2016
Thyroid gland +++ - - Metherell et al., 2005
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216 MRAPs and the melanocortin system
217
218 MRAP and MC2
219 MC2 was initially difficult to express on the surface of cells until an adrenal cell line 
220 was utilised, revealing that MRAP is an essential accessory protein (Metherell et al., 
221 2005). The MC2 receptor only responds to ACTH; ACTH activation of MC2 results in 
222 glucocorticoid-, mineralocorticoid- and steroid-genesis in the adrenal gland. Genetic 
223 variants of MC2R result in severely impaired glucocorticoid production which is 
224 discussed in more detail below. MRAP was found to assist in MC2 transport from the 
225 endoplasmic reticulum to the cell surface (Metherell, et al., 2005), whilst MC2 has 
226 reported to move unassisted to the cell surface (Roy et al., 2007), this finding has been 
227 criticised since extremely low endogenous MRAP2 present in HEK293 cells may 
228 facilitate the MC2 movement (Sebag and Hinkle, 2007). MRAP increases both the 
229 density of surface MC2 and the binding affinity of ACTH to MC2. Measurement of cAMP 
230 in response to Gs activation revealed that MRAP-α elicits a 4-fold greater dose 
231 response than MRAP-β but the maximal cAMP response was higher in the 
232 MC2/MRAP-β cells compared to the MC2/MRAP-α (Roy, et al., 2007). The interaction 
233 of MRAP and MC2 also has an effect on receptor internalisation and recycling (Roy, 
234 et al., 2011).
235
236 The three zones of the adrenal cortex synthesise different steroids: zona glomerulosa, 
237 mineralocorticoids; zona fasciculata, glucocorticoids and zona reticularis, androgens. 
238 The binding of ACTH to MC2 results in the production of cAMP, that in turn stimulates 
239 the protein kinase A (PKA) signalling pathway. In the adrenal gland, this signalling 
240 pathway is responsible for the transcription of genes necessary for steroid synthesis, 
241 such as steroidogenic acute regulatory protein (StAR) (Manna, et al., 2003). The 
242 interaction of MC2 with either of the MRAP isoforms and the response variation (Roy, 
243 et al., 2007) reflects the physiological requirements of these steroids in different 
244 physiological conditions, such as the response to stress or blood pressure changes.
245
246 In addition to MRAP, MRAP2 is expressed in human and rat adrenal glands (Gorrigan, 
247 et al., 2011; Fagerberg, et al., 2014). The response of MC2 depends on which MRAP 
248 it is coupled with, in vitro studies revealed that MC2/MRAP2 transiently transfected into 
249 HEK293 cells required higher concentrations of ACTH to elicit a response compared 
250 to MC2/MRAP transfected cells (Gorrigan, et al., 2011). MRAP and MRAP2 expression 
251 has been described in the foetal adrenal gland suggesting a role of MC2/MRAP and or 
252 MC2/MRAP2 in the adrenal differentiation and proliferation (Gorrigan, et al., 2011). 
253 This is supported by the phenotype of MRAP-/- mice which have disrupted adrenal 
254 gland development with no apparent zonation in the adrenal cortex, without in utero 
255 corticosterone supplementation, the majority of these MRAP-/- mice died at birth 
256 (Novoselova, et al., 2018). MRAP-/- mice had disrupted adrenal progenitor cell 
257 differentiation due to impaired sonic hedgehog and WNT4/β-catenin signalling 
258 (Novoselova, et al., 2018).
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260 MRAPs and other melanocortin receptors
261
262 The melanocortin receptors are expressed throughout the body and have established 
263 roles in different tissues. There is great interest in the involvement of MRAPs and the 
264 surface expression of melanocortin receptors, MC1,3-5. These G-coupled protein 
265 receptors are activated by melanocortin peptides: proopiomelanocortin (POMC) and 
266 the peptides derived from POMC: adrenocorticotropic hormone (ACTH), alpha-, beta- 
267 or gamma-melanocyte stimulating hormone (α-MSH, β-MSH and γ-MSH). ACTH is 
268 further cleaved into: ACTH (1-39), ACTH (1-17), ACTH (1-10), α-MSH and deacetyl α-MSH 
269 (Wakamatsu, et al., 1997). Unlike MC2 which only responds to ACTH, these MCs, 
270 respond with varying affinity to the endogenous melanocortin peptides and activating 
271 different signalling pathways, accounting for MC functional variability. Agouti related 
272 protein (AgRP) is an endogenous antagonist of MC3 and MC4 (Ollmann, et al., 1997; 
273 Fong, et al., 1997). MRAPs regulate both the expression and the response of the other 
274 MCs. Although MRAPs had no effect on the MC1 and MC3 cell surface expression in 
275 in vitro studies with CHO cells; MC1, MC3, MC4 and MC5 became less sensitive to the 
276 synthetic α-MSH analogue, NDP-MSH, when co-expressed with either MRAP or 
277 MRAP2 (Chan, et al., 2009).  
278
279 As described above, MC2 and the MRAPs are important for adrenal gland 
280 development. MC5 expression has been described in the foetal adrenal gland and is 
281 suggested to have a role in foetal development (Nimura, et al., 2006). The role of 
282 MRAP and MRAP2 regulating adrenal differentiation, may be through interaction with 
283 either MC2, MC5 or a heterodimer of both, since heterodimerisation of MC receptors 
284 has been reported (Mandrika, et al., 2005).
285
286 MC1 is well characterised in stimulating melanin synthesis, skin (or retinal) 
287 pigmentation occurs through the oxidation of tyrosine resulting in the formation of 
288 either eumelanin (brown pigmentation) or pheomelanin (yellowish-red pigmentation). 
289 MC1 is expressed in both melanocytes and keratinocytes, as are POMC, ACTH and 
290 the prohormone convertases 1 and 2. α-MSH is the MC1 agonist, activating cAMP and 
291 PKA signalling pathways which ultimately activate the microphthalmia transcription 
292 factor (MITF) and tyrosinase transcription (Beaumont, et al., 2009). The resultant 
293 pigmentation protects the skin from the DNA damaging effects of the ultraviolet 
294 radiation. The variability in skin colour is due to loss of function alleles in MC1R single 
295 gene mutation which also increase the incidence of skin cancer and melanoma 
296 (Sánchez-Laorden, et al., 2007). Whilst mutations of MRAP2 do not cause 
297 disturbances in skin pigmentation, the phenotypic characteristics of MRAP mutations 
298 have included skin hyperpigmentation, as well as high plasma ACTH concentrations 
299 (Jain et al., 2011). Expression of MRAP and MRAP2 in skin is very low (Table 1) a 
300 lack of functional MC2 in MRAP mutation may result in higher circulating ACTH and 
301 consequently MC1 hyperactivity impacting upon skin pigmentation.
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303 The ratio of MRAP2 to the melanocortin receptor may have an important effect on the 
304 melanocortin signalling;  a 1:4 ratio of MC4 :MRAP2 gave greatest cAMP response to 
305 α-MSH whilst a 4:1 ratio of MC4 :MRAP2 reduced cAMP below mock transfected cells 
306 (Schonnop, et al., 2016). Further work is required to elucidate the role of MRAP2 on 
307 MCs the MRAP2 construct design, cell type, melanocortin peptide used to stimulate 
308 transfected cells and technique to measure MC activation are important factors to 
309 consider in interpreting this complex interaction. 
310 In zebrafish two MRAP2 isoforms have been reported (mrap2a and mrap2b) and the 
311 expression of these varies during development; the expression of mrap2a was found 
312 to be present from day 1 of embryogenesis, as was mc4r, however there was little 
313 expression of mrap2b (Sebag, et al., 2013). Knockdown of mrap2a with antisense 
314 morpholinos significantly decreased growth, however, when the mrap2a was knocked 
315 down in mc4r null fish the effect was less marked; in the embryo, mrap2a inhibits MC4 
316 signalling. AgRP is an MC4 antagonist, if both AgRP and mrap2a were knocked down 
317 there was a significant impairment of growth and they are proposed to collaborate 
318 inhibiting MC4 constitutive activity (Sebag, et al., 2013).
319 In contrast the mrap2b isoform was highly expressed in adult zebrafish, and reduced 
320 MC4 constitutive activity and sensitized MC4 to the agonist α-MSH; the mrap2b has 
321 homology to mouse MRAP2 (Sebag, et al., 2013). It was suggested that this switch in 
322 the mrap2 expression may facilitate a change in metabolism to enable free-feeding 
323 once embryonic development was complete.
324 MRAP and familial glucocorticoid deficiency (FGD)
325
326 Glucocorticoids modulate the stress response through the hypothalamic-pituitary-
327 adrenal (HPA) axis and mediate negative feedback control over the corticotropic 
328 releasing hormone (CRH) in the hypothalamus, as well as ACTH release from the 
329 pituitary gland. MRAP2, expression has been reported in hypothalamus, adrenal and 
330 pituitary glands (see table 1) alongside evidence of the melanocortin ligands (Chaly, 
331 et al., 2016). These findings suggest the control of the response may be moderated 
332 by the melanocortin receptors, with the assistance of the MRAPs, at all three levels of 
333 the HPA axis.
334
335 Familial glucocorticoid deficiency (FGD) is characterised by a poor response by the 
336 adrenal cells to adrenocorticotropic hormone (ACTH) leading to cortisol deficiency. As 
337 described above, the MRAPs have an important role stabilising the MC receptors and 
338 facilitating ACTH signalling. FGD is an autosomal recessive disease with 25% of the 
339 cases due to different MC2R mutations (FGD-1), 5% of cases relate to the 
340 steroidogenic acute regulatory protein (StAR) but around 50% of the FGD cases had 
341 an unidentified genetic background. Single nucleotide polymorphism (SNP) array 
342 genotyping of FGD cases revealed that 20% were linked to mutations in the MRAP 
11
343 sequence (FGD-2) (Metherell, et al., 2005). The discovery of MRAP as an essential 
344 accessory protein for MC2 prompted further investigations into the mechanisms 
345 underlying FGD-1. 
346 The MC2R coding sequence lies predominantly in one exon, therefore, splicing 
347 mutations are very rare and missense mutations preserve a residual function, thus, 
348 they are associated with a milder or later onset of the disease. FGD-1 occurs in early 
349 childhood with hypoglycaemia, developmental delay and frequent infections, all due 
350 to low cortisol levels. The reduced receptor sensitivity to ACTH leads to increased 
351 circulating ACTH concentrations which are associated with hyperpigmentation of the 
352 skin and tall stature. These latter signs are thought to result from increased MC1 
353 stimulation and estradiol synthesis by excessive circulatory ACTH levels (Imamine, et 
354 al., 2005). 
355 The cell lines HEK293 and CHO do not express melanocortin receptors and provide 
356 a useful in vitro model for transfection with the MRAPs and the MCs. Chung and 
357 colleagues investigated 24 reported MC2 polymorphisms with MRAP using cAMP 
358 reporter assays and cell surface analyses, they found that two thirds of these SNP 
359 mutations impaired MC2 receptor transport to the cell surface, despite interacting with 
360 MRAP, and resulted in a failure of MC2 receptor to respond to ACTH (Chung, et al., 
361 2008).  
362
363 Unlike MC2R mutations, almost all the mutations occurring in the MRAP are 
364 homozygous non-sense or splice-site mutations which cause severe truncation or 
365 ablation of the MRAP protein (Jain, et al., 2011), (See table 2). Those mutations were 
366 found to be associated with severe glucocorticoid deficiency immediately after birth or 
367 in early infancy with seizures due to hypoglycaemia. Cases of the FGD-2 have been 
368 reported where there is a later onset and a milder presentation of the symptoms. 
369 Sequencing the genome of individuals with later onset glucocorticoid deficiency 
370 revealed a homozygous missense (c.175T>G) mutation that caused an aspartame to 
371 tyrosine substitution at position 59 (N59Y). Whilst another case was reported a 
372 missense (c.76T>C) which led to an alanine to valine substitution at position 26 (V26A) 
373 (Hughes, et al., 2010).
374
375 MRAP-/- mice do not survive after birth without the intervention of in utero 
376 corticosterone and had impaired adrenal gland development (Novoselova, et al., 
377 2018). MRAP is likely to have a major role in adrenal gland development and the 
378 severity of the FGD-2 could be due to underdevelopment of this gland. Although 
379 MRAP2 is also expressed in the adrenal gland, it did not seem to compensate for 
380 absent or mutated MRAP and therefore, might not have a role in the pathogenesis of 
381 FGD. However, as there are still about 50% of FGD cases with unidentified mutations, 
382 further nucleotide sequencing and genome analysis of FGD individuals may reveal a 
383 role of MRAP2.
384
385 Whilst MRAP genetic mutations leading to glucocorticoid deficiency are rare, the use 
386 of synthetic glucocorticoids for inflammatory disorders and autoimmune diseases is 
12
387 widespread. A side-effect of synthetic glucocorticoid treatment is adrenal insufficiency, 
388 characterised by the failure of the adrenal gland to respond to ACTH. In a rat model, 
389 five day exposure of methylprednisolone reduced ACTH and corticosterone 




394 Table 2: Human MRAP mutations which have been described to be associated with 
395 familial glucocorticoid deficiency-type 2. * This mutation in MRAP sequence causes 










Missense G >A-1 Met1Ile Disruptive (Metherell, et al., 2005)
Missense C >A-11 Tyr11Termination Disruptive (Metherell, et al., 2005)
Missense T >C-26 Val26Ala Disruptive (Hughes, et al., 2010)
Missense T >G-59 Tyr59 Asp Disruptive (Hughes, et al., 2010)
Missense T >C-76 Val76Ala Disruptive (Hughes, et al., 2010)












Deletion c.IVS3ds+1delG - Disruptive (Metherell, et al., 2005)




400 MRAP2 and Appetite control
401
402 Appetite control comprises a complicated neuroendocrine circuit involving several 
403 hormones, the sympathetic and parasympathetic nervous system and some elements 
404 of the limbic system. MC4 regulates energy expenditure and appetite control and has 
405 been found in areas of the brain associated with energy homeostasis: MC4R mRNA 
406 has been detected in the paraventricular nucleus (PVN), ventromedial, medial preoptic 
407 and the supraoptic nucleus of the hypothalamus; all of which are integrated in 
408 controlling feeding behaviour (Siljee, et al., 2013). In the PVN, MC4R was detected in 
409 transcription factor single minded 1 (SIM1+) expressing neurones, a population of 
410 neurones known to regulate food intake and  mediate MC4 signalling through a 
411 glutamatergic pathway (Xu, et al., 2013). The MC4 agonist setmelanotide is in clinical 
412 trials for treating severe obesity with underlying genetic causes (Kühnen, et al., 2016; 
413 Clément, et al., 2018).  MC4R-/-  transgenic mice are severely obese and studies with 
414 these animals supported the involvement of MC4 in appetite control, they had 
415 hyperphagia and were non-responsive to melanotan II (MTII), an α-MSH analogue 
416 (Marsh, et al., 1999). α-MSH is released by POMC neurons in the arcuate nucleus in 
417 response to sensory input from the periphery, this in turn stimulates PVN-MC4 
418 signalling leading to reduced appetite. Whilst leptin hunger signalling to the 
419 counteracting agouti-related peptide neurons causes the inactivation of the same 
420 PVN, leading to increased appetite. This is a simplified account of how MC4 is involved 
421 in controlling feeding behaviour. 
422
423 MRAP2 was found to be expressed at high levels in the brain and in areas that are 
424 associated with appetite control, where MC4 has been comprehensively described 
425 (Liang et al., 2018; Bruschetta et al., 2018; Silijee et al 2013). Similar to transgenic 
426 MC4R-/- mice,  both whole body MRAP2-/- and brain targeted MRAP2-/- mice were 
427 morbidly obese, however, MRAP2-/- mice do not show signs of hyperphagia or reduced 
428 energy consumption (locomotion and body temperature), they have normal expression 
429 of POMC but reduced AgRP levels; and they respond to MTII treatment (Asai, et al., 
430 2013). Deletion of both MC4R and MRAP2 produced mice that were less obese than 
431 single deletion MC4R-/- mice. Exposure of MC4R/MRAP2 transfected cells with α-MSH 
432 increases cAMP production compared to MC4R expressing cells, further suggesting 
433 an interaction between MC4 and MRAP2  (Asai, et al., 2013). MRAP2 was also found 
434 to interact with MC3, cAMP production increased in MC3R /MRAP2 transfected cells 
435 in response to α-MSH compared to MC3R expressing cells (Asai, et al., 2013).
436 MRAP2 might be involved in an energy homeostasis/feeding behaviour circuit 
437 independently of MC4. MC3 is perceived to have a minor role in energy homeostasis, 
438 MC3R knockout mice have an obese phenotype but with a reduced lean body mass 
439 and reduced appetite (Chen, et al., 2000). MC3R is expressed on the POMC neurons 
440 in the arcuate nucleus and thought to be exerting autocrine feedback control (Lee, et 
441 al., 2008). MC3R, MC4R and MRAP2 have been observed in chicken hypothalamus; 
442 chicken (c)MRAP (a homolog of MRAP2) was found to enhance the constitutive 
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443 activity of ACTH treated c MC3R /c MC4R transfected cells in a CRE-luciferase 
444 reporter assay (Zhang, et al., 2017). 
445
446 MRAP2 interactions with non-melanocortin receptors
447
448 The role of MRAP2 in mediating energy homeostasis and feeding behaviour extends 
449 beyond the melanocortin receptors. MRAP2 is expressed in the AgRP neurones, 
450 aforementioned AgRP is an MC4 antagonist;  MRAP2 may regulate the AgRP neuronal 
451 activity, since deletion of MRAP2 resulted in reduced AgRP expression and inhibited 
452 AgRP orexigenic activity in response to starvation (Srisai, et al., 2017). The MRAP2-
453 AgRP effect may explain the reduced food intake reported in MRAP2-/- mice.  GHSR-
454 1a (growth hormone secretagogue receptor 1a) is a receptor found in the arcuate 
455 nucleus of the hypothalamus and binds ghrelin, which is released by the stomach, 
456 sending sensory input to stimulate feeding via AgRP neurones. Srisai et al described 
457 MRAP2 to enhance the signalling of GHSR-1a (Srisai, et al., 2017), via Gαq/11 
458 however, MRAP2 independently inhibits β-arrestin recruitment and signalling (Rouault 
459 et al., 2020). Whilst MRAP2 was found to stimulate GHSR-1 and thus feeding, it was 
460 also found to induce feeding by a counteracting mechanism, suppressing the 
461 prokineticin receptor 1 (PKR-1). PKR-1 has a wide tissue distribution and mediates 
462 several functions including suppressing food intake. Measurement of surface density 
463 and surface expression of tagged-PKR-1 in MRAP2 positive and negative cells 
464 revealed lower PKR-1 surface expression in MRAP2 expressing cells; MRAP2 may 
465 not contribute to PKR-1 transport to the cell surface (Chaly, et al., 2016).  In the 
466 presence of MRAP2, PKR-1 was found to have reduced signalling, as lower production 
467 of cAMP and IP3 were observed, respectively in the CRE-luciferase and IP-One 
468 assays (Chaly, et al., 2016).
469
470 An MRAP2/orexin receptor (OX1R) interaction has been described, OX1R is a 
471 hypothalamic receptor expressed in the PVN which stimulates food intake. MRAP2 
472 was found to downregulate the surface expression of OX1R and inhibit OX1R 
473 signalling (Rouault et al., 2017). This study mapped the MRAP2 domains and found 
474 the C-terminal domain of MRAP2 inhibited signalling of both OX1R and PKR-1. The 
475 MRAP2 N-terminal 23-33 domain was involved in inhibiting the OX1R transport to the 
476 cell surface; and the N-terminal 34-43 domain was suggested to exert negative 
477 regulatory control over the MRAP2 activity (Rouault, et al., 2017). A distinct region of 
478 the MRAP2 N-terminus, from that required for OX1R and PKR-1, is suggested to 
479 regulate GHSR-1a signalling (Rouault et al., 2020).  
480
481
482 MRAP2 and obesity 
483
484 Polygenic obesity is affected by genetics, life-style and environmental factors which 
485 predispose to increased appetite and reduced energy expenditure; whole genome and 
486 exome sequencing have been invaluable to identify genetic factors. Monogenic 
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487 obesity has a negligible environmental influence, obesity is usually very severe and 
488 occurs in early childhood. A role for MRAP2 in the pathogenesis of obesity was 
489 suggested following a realisation that it regulates MC4, which, as discussed above, is 
490 essential for energy homeostasis and feeding behaviours. MRAP2 knockout mice 
491 have severe early onset obesity (Asai, et al., 2013). Asai et al sequenced the MRAP2 
492 coding regions and the intron-exon boundaries, in both adults and children with 
493 obesity. They discovered four genetic variants, one which resulted in a non-functional 
494 MRAP2 (E24X, see Table 3). The other three rare variants were towards the C-
495 terminus and considered to have less impact on obesity (Asai et al., 2013 - see table 
496 3). The different functional domains in the MRAP2 observed by Rouault et al., (2017), 
497 might suggest that these variants could influence interactions of MRAP2 / MC4. Eight 
498 more genetic variants of MRAP2 have been detected (3 intronic; 2 synonymous; 2 
499 coding and one synonymous; see table 3) following mutational sequencing of the 
500 MRAP2 coding region of extremely obese individuals (Schonnop, et al., 2016), which 
501 were absent in the control group. This study also reported reduced MC4 signalling 
502 when co-transfected with the nonsynonymous MRAP2 mutant (p.Gln174Arg) in 
503 HEK293 cells (Schonnop, et al., 2016). Studies of the 6q14.1-6q16.3 region revealed 
504 SIM1+ and MRAP2 variants in patients with Prader-Willi like-syndrome (Geets, et al., 
505 2016). 
506
507 The mechanism by which MRAP2 deletion causes obesity is not clearly understood 
508 and predicted to be due to effects on MC4. However, RT-qPCR analysis of 
509 hypothalamus from MRAP2tm1a/tm1a (transgenic mice with targeted exon 4 deletion) 
510 showed normal MC4R PVN content. In contrast, there was a 50 % reduction in the 
511 SIM1+ in the PVN and decreased PVN expression of oxytocin, arginine vasopressin, 
512 corticotrophin-releasing hormone and thyrotropin-releasing hormone (Novoselova, et 
513 al., 2016). MRAP2tm1a/tm1a mice also had raised cholesterol and lipoprotein (HDL and 
514 LDL) concentrations, consistent with observations in MC4 deficient mice; there is a 
515 suggestion that  SIM1+ is either activated downstream of MC4 (Novoselova, et al., 
516 2016) or mediates the MC4 function within the hypothalamic PVN (Xu, et al., 2013). 
517
518 Although mutations in the MRAP2 cause an early onset obesity like MC4R mutations, 
519 Asai et al. (2013) observed no change in the feeding or energy expenditure patterns 
520 in the MRAP2 knockouts compared to the MC4R knockouts. The transgenic mice used 
521 by Novoselova et al which have a different genetic background, show some changes 
522 in the feeding behaviour. These two reports preceded reports that MRAP2 interacts 
523 with the non-melanocortin GPCRs: GHSR-1a, ORX1 and PKR-1. This raises a 
524 possibility that, the obesity pathologies observed in MRAP2 transgenic mice could 
525 involve pathways outside of melanocortin signalling.
526
527 The MRAP2 exon regions were sequenced in a cohort of 9418 subjects, and 23 rare 
528 heterozygous variants were identified which independently increase the risk of obesity 
529 (Baron, et al., 2019). To elucidate a molecular mechanism these variants were co-
530 transfected in CHO cells with MC4R and the cAMP production recorded in response 
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531 to ACTH or α-MSH. Seven MRAP2 variants (c.3-7 del, G31V, F62V, F62C, N77S, 
532 K102* and P195L) decreased cAMP produced in response to ACTH or α-MSH. The 
533 variants C5-5del, c.3-7 del, G31V, F62V, F62C, N77S, K102* and P195L were 
534 associated with obesity (table 3), the authors remarked that 75% of the carriers of 
535 MRAP variants also displayed an abnormal eating behaviour (Baron, et al., 2019). 
536 Lep, LepR, MC4R, PCSK1, POMC and SIM1 are implicated in monogenic obesity, 
537 however, individuals with MRAP2 variants also have higher hypertension and 
538 hyperglycaemia (Baron, et al., 2019). As mentioned above, Srisai et al reported that 
539 MRAP2 enhances the ghrelin signalling through GHSR-1a, ghrelin receptor has been 
540 described to affect blood pressure regulation (Mao, et al., 2016) and further 
541 investigation of MRAP2 and ghrelin signalling is required to understand the 
542 hypertension phenotype described in these individuals.
543
544 Table 3: MRAP2 mutations associated with obesity in humans. 1- MRAP2 
545 heterozygous mutations detected using coding/intron-exon sequencing of MRAP2 
546 gene in coding exons; 2- two cohort studies with severe obesity; 3- patients with 












Missense G >A-3 Ala3Thr Uncertain significance (Baron, et al., 2019)
Missense G >T-3 Ala3Ser Uncertain significance (Baron, et al., 2019)
Missense C >G-13 Gln13Glu Uncertain significance (Baron, et al., 2019)
Nonsense G >T-24 Glu24Term Disruptive (Asai, et al., 2013)
Missense G >T-31 Gly31Val Disruptive (Baron, et al., 2019)
Missense C >T-32 Pro32Leu Uncertain significance (Baron, et al., 2019)
Missense G >T-40 Ala40Ser Non-pathogenic (Geets, et al., 2016)
Missense T >G-62 Phe62Cys Disruptive (Baron, et al., 2019)
Missense A >G-77 Asn77Ser Disruptive (Baron, et al., 2019)
Missense A >T-88 Asn88Tyr Non-pathogenic (Asai, et al., 2013)
Missense T >C-91 Val91Ala Uncertain significance (Baron, et al., 2019)
Missense G >C-99 Glu99Gln Uncertain significance (Baron, et al., 2019)
Missense A >T-102 Lys102X Disruptive (Baron, et al., 2019)
Missense A >G-113 Arg113Gly Uncertain significance (Baron, et al., 2019)
Missense T >G-114 Ser114Ala Uncertain significance (Baron, et al., 2019)
Missense C >G-115 Leu115Val Non-pathogenic (Asai, et al., 2013)
Missense A >G-121 Asn121Ser Uncertain significance (Baron, et al., 2019)
Missense C >T-125 Arg125Cys Uncertain significance (Baron, et al., 2019)
Missense G >A-125 Arg125His Non-pathogenic (Schonnop, et al., 2016)
Missense C >T-133 His133Tyr Uncertain significance (Baron, et al., 2019)
Missense G >A-137 Ala137Thr Non-Pathogenic (Schonnop, et al., 2016)
17
Missense T >C-162 Met162Thr Uncertain significance (Baron, et al., 2019)
Missense A >G-174 Gln174Arg Non-pathogenic (Schonnop, et al., 2016)
Missense A >G-193 Thr193Ala Uncertain significance (Baron, et al., 2019)
Missense C > T-195 Pro195Leu Disruptive (Baron, et al., 2019)
Missense G >T-203 Asp203Tyr Uncertain significance (Baron, et al., 2019)
Deletion c.-5_5del - Loss of function (Baron, et al., 2019)




554 MRAP and insulin signalling
555 The first description of MRAP came from murine 3T3L1 adipocytes; a novel low 
556 molecular weight protein was found in differentiated adipocytes but not pre-adipocytes, 
557 and in both in brown and white adipose tissue. Initially named fat tissue low molecular 
558 weight protein (FALP) (Xu, et al., 2002) it was subsequently renamed MRAP after 
559 recognition of the MC2 interaction (Metherell, et al., 2005). PPARγ, a regulator of 
560 adipocyte differentiation, activates transcription of MRAP (Kim, et al., 2013). MRAP 
561 was observed in adipocytes at the peri-nuclear membrane, but if adipocytes were 
562 exposed to insulin the distribution changed, with discrete MRAP specks distributed 
563 throughout the cytoplasm (Xu, et al., 2002). 
564 Baron et al reported that siRNA MRAP2 knockdown in EndoC-βH1 cells reduced 
565 insulin secretion (Baron, et al., 2019). In adipocytes, MRAP is required for lipolytic 
566 responses to ACTH through MRAP interaction with Gαs (Zhang, et al., 2018). 
567 Increased insulin sensitivity in response to a high fat diet has been reported in 
568 transgenic mice with MRAP overexpression in adipose tissue, correlating with 
569 decreased plasma triglyceride and cholesterol concentrations. Insulin resistance and 
570 glucose intolerance has also been described in MRAP2 knockout mice (Rouault, et 




575 MC1 and MC3 signalling through α-MSH and ACTH mediate anti-inflammatory 
576 responses downregulating and inhibiting the release of proinflammatory cytokines: 
577 TNF-α, INF-γ, IL-6; inducible nitric oxide synthase and the chemokine receptors CXC1 
578 and 2 whilst stimulating IL-1 release (Catania, et al., 1998; Catania, et al., 2004; 
579 Getting, et al., 2003).  MC3 therapeutics targeted for rheumatoid arthritis and other 
580 chronic inflammatory conditions report side effects of hyperpigmentation and 
581 increased melanoma risk, through hyperstimulation of MC1. Adrenal inflammation is 
582 associated with side effects of synthetic corticosteroids where MRAP2 is 
583 downregulated (Spiga, et al., 2020). Additional investigations may determine whether 





588 MRAP2- Single nucleotide variations related to cancer 
589
590 The BioMuta single-nucleotide variation (SNV) and disease database revealed 
591 MRAP2 SNV to be linked to different types of cancers with varying frequencies. High 
592 frequency of SNV was seen with melanomas and uterine cancers followed by a lower 
593 variation frequency seen in colorectal, lung, stomach and liver cancers (Simonyan, 
594 and Mazumder, 2014). As discussed above MC1R mutations are associated with 
595 melanoma (Sánchez-Laorden, et al., 2007), although not affecting MC1 surface 
596 expression, MRAP2 reduces responsiveness of MC1 to the synthetic α-MSH agonist 
597 NDP-MSH and affects receptor signalling (Chan, et al., 2009).  Other types of cancers 
598 that were showed a lower MRAP2 SNV include breast, thyroid, prostate, pancreas, 
599 urinary tract and brain cancers (Simonyan, and Mazumder, 2014). SNV that are linked 
600 to MRAP2 over-expression included liver, lung and pancreatic cancers, however, SNV 
601 leading to MRAP2 suppression included breast, thyroid and prostate cancers. The 
602 tissue distribution of MRAP2 is shown in table 1; MRAP2 has not been reported in 
603 healthy human liver, thyroid or urinary tract. The association of MRAP2 to a wide 
604 variety of cancers is of interest. However, the potential pathogenesis and involvement 




609 Recently in this journal, MRAP2 was described to be significantly up-regulated in 
610 women with unexplained infertility (D’Aurora, et al., 2019). MRAP-α, MRAP-β and 
611 MRAP2 have low expression in the endometrium (Table 1). Hypertrophy of the uterine 
612 gland epithelium was observed in women with unexplained infertility. The increased 
613 MRAP2 expression suggests that MRAP2 might influence the stability of the 
614 endometrium (D’Aurora, et al., 2019); understanding the roles of MRAP and MRAP2 







622 In summary, genetic variants of MRAP are associated with severe familial 
623 glucocorticoid deficiency, however evidence is emerging that synthetic glucocorticoids 
624 may also disrupt ACTH and MRAP expression resulting in adrenal inflammation. 
625 MRAP2 genetic variants are associated with severe obesity but the phenotypes are 
626 subtly different to the phenotypes observed with MC4R genetic variants. There is a 
627 great deal of interest in the development of melanocortin therapeutics to treat obesity, 
628 as evidenced by setmelanotide, and fully understanding the role of MRAP2 and the 
19
629 interactions with both melanocortin receptors and other GCPR would be of great value. 
630 The use of the MRAP2 knockout and transgenic models have aided understanding of 
631 interactions with the different MCs in metabolic regulation, feeding behaviour and 
632 energy homeostasis. MRAP is detected in areas with absent or extremely low MC2 
633 expression, potentially it also may bind to non-melanocortin receptors. Further studies 
634 with transgenic models and insights from studies of genetic variants may provide 
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